scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
81 hedge funds and large institutions have $291M invested in scPharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 14 closing their positions.
136% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 14
43% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $1.28M
31% more funds holding
Funds holding: 62 → 81 (+19)
30% more capital invested
Capital invested by funds: $223M → $291M (+$67.6M)
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
11.03% more ownership
Funds ownership: 68.75% → 79.78% (+11%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$10.1M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$8.94M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.47M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$6.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$10.1M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$5.06M |
| 3 |
Millennium Management
New York
|
-$4.57M |
| 4 |
Two Sigma Investments
New York
|
-$2.07M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.47M |
SCPH Hedge Fund Activity: Q2 2023 in Review
81 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2023, worth a combined $291M — up 30% from $223M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new SCPH positions and 14 closed out — a net gain of 19 holders — while 21 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $16.9M. The largest seller was Cowen and Company, cutting an estimated $10.1M.
- 81 institutional investors held scPharmaceuticals (SCPH) as of Q2 2023, up from 62 in Q1 2023.
- Funds reported $291M of scPharmaceuticals stock for Q2 2023, up 30% quarter-over-quarter.
- 33 funds opened new scPharmaceuticals positions in Q2 2023 and 14 closed out, a net change of +19 holders.
- The largest scPharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $16.9M added.
- The largest scPharmaceuticals seller in Q2 2023 was Cowen and Company, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2023.